A citation-based method for searching scientific literature

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Gastroenterology 2019
Times Cited: 567



The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
Times Cited: 3093




List of shared articles



Times cited

Reliability of Non-invasive Liver Fibrosis Assessment Tools Versus Biopsy in Pre- and Post-bariatric Surgery Patients with Non-alcoholic Fatty Liver Disease.
Katherine J P Schwenger, Maryam Alali, Yasaman Ghorbani, Sandra E Fischer, Timothy D Jackson, Allan Okrainec, Johane P Allard. Obes Surg 2023
0

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023.
Nuha A ElSayed, Grazia Aleppo, Vanita R Aroda, Raveendhara R Bannuru, Florence M Brown, Dennis Bruemmer, Billy S Collins, Kenneth Cusi, Marisa E Hilliard, Diana Isaacs,[...]. Diabetes Care 2023
0

Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.
Jordan E Lake, Turner Overton, Susanna Naggie, Mark Sulkowski, Rohit Loomba, David E Kleiner, Jennifer C Price, Kara W Chew, Raymond T Chung, Kathleen E Corey. Clin Gastroenterol Hepatol 2022
15

Treatment Candidacy for Pharmacologic Therapies for NASH.
Ian A Rowe, Vincent Wai-Sun Wong, Rohit Loomba. Clin Gastroenterol Hepatol 2022
7

Conventional ultrasound for diagnosis of hepatic steatosis is better than believed.
Christoph F Dietrich, Long Shi, Axel Löwe, Yi Dong, Andrej Potthoff, Zeno Sparchez, Andreas Teufel, Sabine Guth, Jonas Koch, Richard G Barr,[...]. Z Gastroenterol 2022
3

Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan.
Donghee Kim, Peter Konyn, George Cholankeril, Aijaz Ahmed. Clin Gastroenterol Hepatol 2022
18

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala. J Clin Endocrinol Metab 2022
25

Changing clinical management of NAFLD in Asia.
Takuma Nakatsuka, Ryosuke Tateishi, Kazuhiko Koike. Liver Int 2022
4

Clinical Relevance of Selenium with Liver Stiffness and Steatosis Detected by Transient Elastography in Adults.
Xiaohui Liu, Hong Shen, Mingfeng Chen, Jun Shao. Biol Trace Elem Res 2022
1

Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations.
Solène Marie, David K K Tripp, Nathan J Cherrington. Drug Metab Dispos 2022
3

Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them.
S Marciano, M Dirchwolf, M C Torres, J Allevato, C García Dans, B García, F Pollarsky, L Gaite, E Sirotinsky, B Rios,[...]. Rev Gastroenterol Mex (Engl Ed) 2022
0

Advancing the global public health agenda for NAFLD: a consensus statement.
Jeffrey V Lazarus, Henry E Mark, Quentin M Anstee, Juan Pablo Arab, Rachel L Batterham, Laurent Castera, Helena Cortez-Pinto, Javier Crespo, Kenneth Cusi, M Ashworth Dirac,[...]. Nat Rev Gastroenterol Hepatol 2022
105

Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population.
Sheng Yang, Jiawen Cheng, Rui Zhang, Huiwen Sun, Hui Zhang, Sali Lyu, Weiwei Duan. Hepatol Res 2022
2

Evaluation of fibrosis in patients with nonalcoholic fatty liver disease.
Aldo J Montaño-Loza. Rev Gastroenterol Mex (Engl Ed) 2022
0

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.
Nobuharu Tamaki, Veeral Ajmera, Rohit Loomba. Nat Rev Endocrinol 2022
22

Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery.
Pierre Bel Lassen, Nicole Nori, Pierre Bedossa, Laurent Genser, Judith Aron-Wisnewsky, Christine Poitou, Rambabu Surabattula, Mette Juul Nielsen, Morten Asser Karsdal, Diana Julie Leeming,[...]. J Clin Endocrinol Metab 2022
2

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).
. Eat Weight Disord 2022
3

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).
. Nutr Metab Cardiovasc Dis 2022
1

Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis.
Zobair M Younossi, Linda Henry. Endocr Pract 2022
3

The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Salem Alsaqal, Paul Hockings, Håkan Ahlström, Anders Gummesson, Anders Hedström, Johannes Hulthe, Lars Johansson, Heiko G Niessen, Corinna Schoelch, Christian Schultheis,[...]. J Magn Reson Imaging 2022
0

Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD.
Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H Afdhal, Michelle Lai. Hepatol Commun 2022
6

Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
Sami Qadri, Noora Ahlholm, Ida Lønsmann, Paola Pellegrini, Anni Poikola, Panu K Luukkonen, Kimmo Porthan, Anne Juuti, Henna Sammalkorpi, Anne K Penttilä,[...]. J Clin Endocrinol Metab 2022
10

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Jerome Boursier, Hannes Hagström, Mattias Ekstedt, Clemence Moreau, Martin Bonacci, Sandrine Cure, Javier Ampuero, Patrik Nasr, Lilian Tallab, Clémence M Canivet,[...]. J Hepatol 2022
15

Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.
Nobuharu Tamaki, Kento Imajo, Suzanne R Sharpton, Jinho Jung, Nancy Sutter, Nobuyoshi Kawamura, Masato Yoneda, Mark A Valasek, Cynthia Behling, Claude B Sirlin,[...]. Clin Gastroenterol Hepatol 2022
4

Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.
Juan Carlos Rodriguez-Duque, José Luis Calleja, Paula Iruzubieta, Marta Hernández-Conde, Coral Rivas-Rivas, María Isabel Vera, Maria Jose Garcia, Marta Pascual, Beatriz Castro, Agustín García-Blanco,[...]. Clin Gastroenterol Hepatol 2022
3

Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort.
Jacob V DiBattista, Daniel A Burkholder, Anna S Lok, Vincent L Chen. Dig Dis Sci 2022
0

A robust gene expression signature for NASH in liver expression data.
Yehudit Hasin-Brumshtein, Suraj Sakaram, Purvesh Khatri, Yudong D He, Timothy E Sweeney. Sci Rep 2022
2

Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Tiziana Fernández, Macarena Viñuela, Catalina Vidal, Francisco Barrera. PLoS One 2022
7

Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.
Eirini Martinou, Marinos Pericleous, Irena Stefanova, Vasha Kaur, Angeliki M Angelidi. Diagnostics (Basel) 2022
8

Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.
Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q Huang, Rohit Loomba. Hepatol Res 2022
2

Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
Neeta B Amin, Amanda Darekar, Quentin M Anstee, Vincent Wai-Sun Wong, Frank Tacke, Manoli Vourvahis, Douglas S Lee, Michael Charlton, Naim Alkhouri, Atsushi Nakajima,[...]. BMJ Open 2022
0

Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity.
Diego Meneses, Antonio Olveira, Ramón Corripio, María Del Carmen Méndez, Míriam Romero, Isabel Calvo-Viñuelas, Lucrecia Herranz, David Vicent, Ana Isabel de-Cos-Blanco. Endocrinol Diabetes Nutr (Engl Ed) 2022
0

SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
Luigi Mirarchi, Simona Amodeo, Roberto Citarrella, Anna Licata, Maurizio Soresi, Lydia Giannitrapani. Int J Mol Sci 2022
4


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy